You’re all signed up for CFO Slice
Thank you for your interest in our service.
Watch out for a confirmation email from our subscriptions team. Once you have confirmed you will join the worldwide community of thousands of subscribers who are receiving daily CFO intelligence to lead, innovate and grow.
Note: Due to the nature of this message you may find this in your "promotions" or "spam" folders, please check there. If nothing arrives within a few minutes let us know. If you do not receive this email we will be happy to help get you set up.
Adding the email address news@industryslice.com, will help to ensure all newsletters arrive directly to your inbox.
Recent Editions

CFO Slice
According to a report by Morningstar, the potential impact of U.S. President Donald Trump's proposed tariffs on pharmaceuticals and efforts to reduce drug prices is expected to be manageable for major U.S. and European drugmakers. The analysis suggests that while companies may face higher long-term taxes and costs associated with relocating manufacturing to the U.S., the immediate risk from price reductions is "exceedingly low." The report estimates that an initial 15% tariff on pharmaceuticals could peak at about 4% of core profit for the companies examined, after mitigation strategies are implemented.
Full Issue